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INTRODUCTION 
During the last decade. evidence has been collected on 
the central role played by growth stimulating factors 
(GsF) [1-9J and growth inhibiting factors (GiF) [10-12J 
in the mechanism of tissue growth regulation, using dif-
ferent experimental models [13 J. The model of partial 
hepatectomy (PH) in rats has provided numerous findings 
on the existence of this regulatory process. In healthy 
mammals there is a well-defined relationship between 
body weight and liver weight [14]. When this relation-
ship is altered either by surgical resection or by viral and 
toxic noxae. the liver quickly restores its volume [15]. A 
rapid growth of the residual liver mass is observed during 
the first few days after PH. indicating the prevalence of 
GsFs (Fig. I). Later. a gradual decrease in liver growth is 
observed after the appearance of GiFs, which stop the 
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regenerative process when the initial volume of the liver 
is restored (Fig. I). 
Different liver growth factors (GFs) have been identi-
fied and classified. on the basis of their nature, as hor-
monal GF, GsF. and GiF (Table I). Recently, these fac-
tors have also been called initiators. progressors. and 
augmentors [16], on the basis of the time of their inter-
vention in the cell cycle (Fig. 2). 
Initiators are ions. nutrients. and hormones that are 
able to induce the Go-G t transition in quiescent (Go) 
hepatocytes. The rapid increase of the expression of the 
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Fig. !. . Liver mass recovery in rats after 70% hepatectomy. Liver resection was performed as descnbed 
by Hlggms and Anderson 115]. ~fver mass is expressed as percentage of the liver weight in the intact 
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TABLE I. Hormones and Growth Factors Involved in the 
Regulation of Liver Regeneration· 
Hormones 
Prolactin 
Angiotensin 
Vasopressin 
Norepinephrine 
Estradiol 
TJ 
Insulin 
Glucagon 
Growth 
stimulating 
factors (GsF) 
IGF II 
EGF 
TGF-a 
HSS 
HGF 
Growth 
inhibiting 
factors (Gif) 
qdc-~ 
IL-l 
IL-6 
RPM 
*T" triiodo-thyronine: IGF-II. insulin-like growth factor II; EGF. 
epidermal growth factor: TGF-a. transforming growth factor alpha: 
HSS. hepatic stimulatory substance: HGF, hepatocyte growth factor: 
TGF-J3. transforming growth factor beta: IL-l, interleukin 1; IL-2. 
interleukin 2: RPM. rapamycin. 
protooncogenes myc and fos characterizes this phase 
[ II]. Transforming growth factor alpha, hepatocyte 
(H)GF, and epidennal (E)GF, which are defined as pro-
gressors, induce the Go-G. transition and allow hepato-
cytes to progress throughout the cell cycle. These GFs act 
both in vivo and in vitro [5,7,9]. H-ras. K-ras. and p53 
are the biological markers of G .-S progression (II]. 
Hepatic stimulatory substance (HSS), cyclosporin A 
(CyA), FK 506. insulin. and insulin-like growth factor 
(IGF) II have been defined as augmentors [1~OMzK They 
are not active in vitro, while in vivo they stimulate the 
proliferation of hepatocytes that have already completed 
the Go-G I transition. The principal characteristics of 
some of these augmentors. as recently identified by our 
group. are reported here. 
HEPATIC STIMULATORY SUBSTANCE 
HSS is a protein with a molecular weight of 33 kOa. It 
is found in cytosolic extracts of rat [4,8,21.22], rabbit 
[23], and dog [24] livers undergoing a proliferative re-
sponse. The different steps of HSS preparation and puri-
fication are described in our previous papers [4,8], re-
porting, for the purest fraction (Acr-F4), a degree of 
purification of 380.000 times. This fraction is active only 
when administered in vivo and has been shown to be 
active both in the 40% hepatectomized rat model and in 
the portacaval shunt model [8]. In this latter model, it 
induces a proliferative response that exceeds that induced 
by other well-recognized GFs. at a dose of 20 ng/kg/day. 
This highly purified fraction does not stimulate the prolif-
eration of hepatocytes in vitro in the presence or absence 
of either EGF or heparin [4]. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SOS-PAGE) of 
Acr-F4 (Fig. 3) shows the presence of four different 
bands. However, western blot analysis demonstrates spe-
cific immunoreactivity with only one band. having an 
MW of 33 kOa (Fig. 3). Table II describes the physico-
chemical characteristics of HSS as currently recognized 
[8]. 
CYCLOSPORIN A AND FK 506 
In our recent work [17-20,25.26] we have shown that 
eyA and FK 506, two powerful immunosuppressors. 
stimulate hepatocyte proliferation in partially hepatecto-
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Fig. 2. General pattern of the factors modulating liver regeneration and their time of intervention in the 
cell cycle. CyA. cyclosponn A: EGF. epidermal growth factor: HGF. hepatocyte growth factor: HSS. 
hepatic stimulatory substance: rGF. insulin-like growth factor: IL. interleukin: RPM. rapamycin: TGF. 
transforming growth factor. 
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Fig. 3. SDS-PAGE and Western blot analysis of acrylamide F4 (Ac-
F4). For SDS-PAGE (A) final acrvlamide concentration was 16%. in 
Tris 0.377 M. pH 8.8. Fifteen micrograms of protein underwent elec-
trophoresis for 50 minutes at room temperature using 150 V. constant 
voltage. with Tris-HCI 0.125 M and 0.192 M glycine. pH 8.3. as 
reservoir buffer. Western blot analysis (8) was performed using an 
lmmobilon membrane (Millipore). Protein transfer was conducted us-
ing 3-(cyclohexylammo )-I-propano-sulfonic aCId (CAPS) 10 mM with 
10% methanol. pH II. as transfer buffer (90 minutes at 4°C with 70 V 
constant voltage). The membrane was blocked for 30 minutes with 3% 
gelatin in TIBS (Tris-buffered saline with 0.2% Tween 20) and incu-
bated. for 60 minutes. with a specific monoclonal murine antibody 
against hepatic stimulatory substance (HSS) [8). The membrane was 
then washed with TIBS and incubated with a second antibody in 1% 
gelatin. against mouse immunoglobulins. carrying alkaline-phosphate 
substrate. The membrane was washed with TIBS and the immunore-
active band was identified. 
TABLE II. Physicochemical Characteristics of HSS 
Parameter 
Heat resistance 
pH stability 
Alcohol stabtlity 
Resistance to: 
Trypsin 
Chymotrypsin 
Neuroammidase 
+ 
4.5-7.5 
+ 
+ 
mized rats (Fig. 4). The effect of these drugs is mediated 
by their binding with a new family of cytokines called 
immunophilins [27], which are ubiquitous and are spe-
cific for each immunosuppressive agent [28]. 
The role of immunosuppressive agents in liver regener-
ation has been further confirmed by another series of 
experiments using rapamycin (RPM) [26.29]. This drug, 
structurally similar to FK 506. has a negative effect on 
hepatocyte proliferation when administered to 70% hepa-
tectomized rats (Fig. 4). These results indicate that im-
munophilins intluence hepatic regeneration in both stim-
ulatory or inhibitory ways. In addition. they indicate the 
presence in the cells of still unknown endogenous sub-
stances equivalent to FK 506. CyA, and RPM. 
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Recently two theories on the mechanism(s) regulating 
hepatic regeneration have been proposed to answer the 
central question of what starts liver regeneration. In the 
first theory, proposed by Michalopoulos et al. [30], the 
reduction of the liver mass generates in extrahepatic sites 
"signals" that act as complete mitogenic stimuli (Fig. 5). 
Two candidates have shown strong cumulative evidence 
as primary factors in the genesis of this stimulus: norepi-
nephrine [31-33] and HGF [30]. In the second theory, 
proposed by Fausto et al. [11], the plasmatic changes 
induced by PH cause hepatocytes to produce their own 
mitogenic stimuli [transforming growth factor-alpha 
(TGF-et»). In this case autocrine and paracrine loops in-
volving nonparenchymal cells would control liver regen-
eration. keeping stimulatory and inhibitor "forces" stable 
or unbalancing them (Fig. 5). In both cases augmentors. 
which act on the G1-S transition. remain an important 
step in the chain of events involved in the control of 
regeneration. 
The findings regarding the stimulatory activity of FK 
506 and Cy A have led investigators to explore another 
important aspect of the regenerative process, i.e., intra-
cellular signal transduction. Actually, mitogenic stimuli 
are known to produce two types of intracellular signal 
transduction (Fig. 6). Peptides such as vasopressin, 
bombesin. and bradikinin bind to a guanine nucleotide 
protein. which activates a specific phospholipase C with 
formation of inositol trisphosphate [34J. On the other 
hand, growth factors such as EGF. platelet-derived 
growth factor (PDGF), and TGF-et bind to receptors hav-
ing as internal domain a tyrosine kinase protein that can 
produce inositol trisphosphate either directly or through 
the same specific phospholipase C activated by the 
growth factors of the previous group [34]. In both cases 
inositol trisphosphate. which acts as transducer. binds to 
specific receptors of the endoplasmatic reticulum. deter-
mining a release of calcium and an increase of intracellu-
lar free-calcium concentration (Fig. 6). The calcium in-
crease and the related pH change seem to be important 
steps leading to DNA replication. 
Recently Schreiber et a!. [28] have demonstrated that 
when Cy A and FK 506 bind to their specific immuno-
philins they constitute a drug-immunophilin complex 
(Fig. 7) that. in turn. binds with high affinity to the 
intracellular proteins calcineurin and calmodulin, forming 
a pentameric complex (Fig. 7). This penta me ric complex 
has a high affinity for calcium channels and determines. 
like inositol triphosphate. a calcium release from the 
endoplasmic reticulum. followed by DNA replication 
(Fig. 8). 
The data obtained on liver regeneration using RPM 
suggest that this immunosuppressor has an opposite ef-
fect on calcium transport and therefore inhibits hepato-
cyte proliferation. 
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Fig. 4. Effect of immunosuppressive agents on liver regeneration 
after 70% hepatectomy. [.lHJthymldine incorporation and percentage 
of mitoses in normal and 70% hepatectomized rats treated or not 
treated with cyclosporin A (CyA). FK 506. and rapamycin (RPM). The 
animals were given oral CyA and intramuscular FK 506 or RPM at iO 
mg, I mg. and 0.3 mg/kg body weight, respectively. for 3 days before 
;,urgery and again Just after completing hepatic resection [15 J. Values 
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are the means from at least 15 rats::!: SD. *. significantly different 
from 70% hepatectomized rats (P < .05). **. significantly different 
from 70% hepatectomized rats (P < .0 I) and CyA-treated 70% hepa-
tectomized rats (P < .05). ***. significantly different from 70% hepa-
tectomized rats (P < .01). Vehicle injections did not influence 
l'HJthymidine incorporallon and percentage of mitoses in normal and 
70% hepatectomized rats. PH. parllal hepatectomy. 
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Fig. 5. Possible mechanisms for the control of hepatic regeneration. The factors controlling hepatocyte 
proliferation are given. as described by Michalopoulos [I [ (A) and Fausto [7) (B). Norepinephrine. 
vasopressin. and angiotensin potentiate GsF action and reduce GiF influence. For abbreviations. see 
Figure 2 legend. 
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Fig. 6. Signalling pathways of growth factors. R. cell surface recep-
lor; G. guanine nucleotide binding protein: PhIC. phospholipase C: m~K 
phosphatidvlinosltol biphosphate: TK_ tyrosine kinase: In. inositol: 
DG. diacylglycerol: PooF. platelet·denved growth factor. 
Fig. 7. Interaction of CyA and FK 506 immunophilin complex with 
speCific intracellular proteins. CyP. cyclophilin: FKBP. FK binding 
protein: CaM. calmodulin: CNA·CNB. calcineurin: 1m. immuno-
philin: D. drug. 
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Fig. 8. [ntracellular signalling pathway of FK 506 and CyA. R, cell surface receptor; G. guanine 
nucleotide binding protein; PhIC. phospholipase C; P2 • phosphatidylinositol biphosphate; TK, tyrosine 
kinase; In. inositol; DG. diacylglycerol; CaM. calmodulin; CNA-CNB, calcineurin; 1m, immunophilin; 0, 
drug. 
CONCLUSIONS 
In the last decade important new data have enriched 
our knowledge of the mechanisms regulating liver regen-
eration. These findings, essentially concerning growth 
stimulating factors, have led to the identification of a new 
class of GFs defined as "augmentors." On the other hand, 
very little is known about growth inhibiting factors. 
which undoubtedly play an important role in the control 
of cell proliferation. 
Studies on the effect of immunosuppressive agents on 
liver regeneration have recently demonstrated that these 
agents can act either as growth inhibitors or growth stim-
ulators. Moreover. such findings give indirect evidence 
of the existence of endogenous analogues of CyA, FK 
506, and RPM that may constitute a connection between 
the immune system and the growth control system. It is 
likely that a deeper knowledge of all these factors will 
also help to define, in the near future, the mechanisms 
responsible for carcinogenesis. 
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